References
- 1JankovicJParkinson’s disease: Clinical features and diagnosisJ Neurol Neurosurg Psychiatry200879368376doi:http://dx.doi.org/10.1136/jnnp.2007.13104518344392
- 2MilanovIA cross-over clinical and electromyographic assessment of treatment for parkinsonian tremorParkinsonism Relat Disord200186773doi:http://dx.doi.org/10.1016/S1353-8020(00)00077-811472883
- 3KrausPHLemkeMRReichmannHKinetic tremor in Parkinson’s disease – an underrated symptomJ Neural Transm2006113845853doi:http://dx.doi.org/10.1007/s00702-005-0354-916804646
- 4FleischmanDAWilsonRSSchneiderJABieniasJLBennettDAParkinsonian signs and functional disability in old ageExp Aging Res2007335976doi:http://dx.doi.org/10.1080/0361073060100637017132564
- 5MiyasakiJMMartinWSuchowerskyOWeinerWJLangAEPractice parameter: initiation of treatment for Parkinson’s disease: An evidence-based review: report of the Quality Standards Subcommittee of the American Academy of NeurologyNeurology2002581117doi:http://dx.doi.org/10.1212/WNL.58.1.1111781398
- 6NagatsuaTSawadabML-dopa therapy for Parkinson’s disease: past, present, and futureParkinsonism Relat Disord200915S3S8doi:http://dx.doi.org/10.1016/S1353-8020(09)70004-519131039
- 7StathisPKonitsiotisSAntoniniADopamine agonists early monotherapy for the delay of development of levodopa-induced dyskinesiasExpert Rev Neurother20151517doi:http://dx.doi.org/10.1586/14737175.2015.100174725576088
- 8KatzenschlagerRSampaioCCostaJLeesAAnticholinergics for symptomatic management of Parkinson’s diseaseCochrane Database Syst Rev20032CD003735doi:http://dx.doi.org/10.1586/14737175.2015.100174712804486
- 9SchadtCRDuffisEICharlesPDPharmacological treatment of disabling tremorExpert Opin Pharmacother20056419428doi:http://dx.doi.org/10.1517/14656566.6.3.41915794733
- 10de LauLMBretelerMMEpidemiology of Parkinson’s diseaseLancet Neurol20065525535doi:http://dx.doi.org/10.1016/S1474-4422(06)70471-916713924
- 11RahimiFDebickiDRoberts-SouthACBeeCBapatPJogSDynamic decomposition of motion in essential and parkinsonian tremorCan J Neurol Sci201542116124doi:http://dx.doi.org/10.1017/cjn.2015.1225702954
- 12KimSYiannikasCMahantNVucicSFungVTreatment of proximal upper limb tremor with botulinum toxin therapyMov Disord201329835838doi:http://dx.doi.org/10.1002/mds.2573924519658
- 13PacchettiCManciniFBulgheroniMet alBotulinum toxin treatment for functional disability induced by essential tremorNeurol Sci20002134935311441571
- 14BrinMFLyonsKEDoucetteJet alA randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremorNeurology2001561523152811402109
- 15PullmanSLGreenePFahnSPedersenSFApproach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patientsArch Neurol1996536176248929169
- 16LimEQuekASeetRAccurate targeting of botulinum toxin injections: how to and whyParkinsonism Relat Disord201117S34S39doi:http://dx.doi.org/10.1016/j.parkreldis.2011.06.01621999895
- 17JankovicJSchwartzKBotulinum toxin treatment of tremorsNeurology199141118511881866001
- 18TroschRMPullmanSLBotulinum toxin a injections for the treatment of hand tremorsMov Disord199496016097845399
- 19SupukTBajdTJurilloGAssessment of reach-to-grasp trajectories toward stationary objectsClin Biomech201126811818doi:http://dx.doi.org/10.1016/j.clinbiomech.2011.04.007
- 20CasellatoCZorziGPedrocchiAFerrignoGNardocciNReaching and writing movements: sensitive and reliable tools to measure genetic dystonia in childrenJ Child Neurol201126822829doi:http://dx.doi.org/10.1177/088307381039299721421904
- 21RahimiFBeeCDebickiDRobertsACBapatPJogMEffectiveness of BoNT A in Parkinson’s disease upper limb tremor managementCan J Neurol Sci20134066366923968939
- 22RozmanJBartolicARibaricSA new method for selective measurement of joint movement in hand tremor in Parkinson’s disease patientsJ Med Eng Technol20073130531117566934
- 23ConnollyBSLangAEPharmacological treatment of Parkinson disease: a reviewJAMA201431116701683doi:http://dx.doi.org/10.1001/jama.2014.365424756517
- 24JankovicJSchwartzKClemenceWAswadAMordauntJA randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremorMov Disord1996112502568723140
- 25HendersonJMGhikaJAVan MelleGHallerEEinsteinRBotulinum toxin A in non-dystonic tremorsEur Neurol19963629358719647
- 26Machowska-MajchrzakAPierzchalaKPietraszekSLabuz-RoszakBEssential tremor – assessment of tremor accelerometric parameter’s symmetry and the relationship between hand dominance and severity of tremorNeurol Neurochir Pol20114512112721574115
- 27RahimiFBeeCSouthADebickiDJogMVariability of hand tremor in rest and in posture – a pilot studyConf Proc IEEE Eng Med Biol Soc20112011470473doi:http://dx.doi.org/10.1109/IEMBS.2011.609006722254350
- 28Van Der WaltASungSSpelmanTet alA double-blind, randomized, controlled study of botulinum toxin type A in MS-related tremorNeurology2012799299doi:http://dx.doi.org/10.1212/WNL.0b013e31825dcdd922753445
